- Home
- PLRX vs ATRA Comparison
PLRX vs ATRA Comparison
Compare PLRX & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLRX | ATRA |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.3M | 99.1M |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | PLRX | ATRA |
|---|---|---|
| Price | $1.53 | $13.17 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 3 |
| Target Price | $3.79 | ★ $21.00 |
| AVG Volume (30 Days) | ★ 762.4K | 67.9K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.97 |
| Revenue | N/A | ★ $151,930,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $7.02 |
| Revenue Growth | N/A | ★ 51.27 |
| 52 Week Low | $1.10 | $5.01 |
| 52 Week High | $15.80 | $18.71 |
Technical Indicators
Market Signals| Indicator | PLRX | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 42.21 | 47.57 |
| Support Level | $1.48 | $12.93 |
| Resistance Level | $1.63 | $15.12 |
| Average True Range (ATR) | 0.10 | 1.02 |
| MACD | -0.01 | 0.09 |
| Stochastic Oscillator | 10.45 | 53.32 |
Price Performance
Historical ComparisonAbout PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).